ISEE

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ARNC, HMPT, ISEE, CHRA

Retrieved on: 
Thursday, May 25, 2023
Glossary of cue sports terms, ARNC, ISEE, Sale, Iver C. Olsen, Arconic, Charah, Advertising, CHRA, OTC, Fraud, NYSE, Security (finance)

If you are an Arconic shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are an Arconic shareholder, click here to learn more about your rights and options .
  • If you are a Home Point shareholder, click here to learn more about your rights and options .
  • Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

Lifshitz Law PLLC Announces Investigations of RUTH, MGTA, MDWT, and ISEE

Retrieved on: 
Sunday, May 14, 2023
Telephone, Sale, ISEE, MGTA, Advertising, Hewlett, Life insurance, Online shopping

Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of MGTA and Dianthus Therapeutics, Inc.

Key Points: 
  • Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of MGTA and Dianthus Therapeutics, Inc.
  • Lifshitz Law PLLC announces investigation into possible breach of fiduciary duties in connection with the sale of MDWT to Antarctica Capital for $27.00 per share in cash.
  • Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of ISEE to Astellas Pharma Inc. for $40.00 per share in cash.
  • The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MDWT, ARNC, ISEE, CHRA

Retrieved on: 
Tuesday, May 9, 2023
ARNC, ISEE, Sale, Iver Johnson AMAC-1500, Arconic, Charah, Advertising, CHRA, OTC, Fraud, NYSE, Security (finance)

If you are a Midwest shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a Midwest shareholder, click here to learn more about your rights and options .
  • If you are an Arconic shareholder, click here to learn more about your rights and options .
  • Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – CVT, NATI, USX, ISEE

Retrieved on: 
Thursday, May 4, 2023
ISEE, USX, Empire, NATI, Sale, Monteverde, National Instruments, CVT, NYSE, Blackstone Inc., Security (finance)

National Instruments Corp. (NASDAQ: NATI ), relating to its proposed sale to Emerson Electric Co.

Key Points: 
  • National Instruments Corp. (NASDAQ: NATI ), relating to its proposed sale to Emerson Electric Co.
  • Under the terms of the agreement, NATI shareholders are expected to receive $60.00 in cash per share they own.
  • Under the terms of the agreement, USX shareholders are expected to receive $6.15 in cash per share they own.
  • Under the terms of the agreement, ISEE shareholders are expected to receive $40.00 in cash per share they own.

IVERIC BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of IVERIC bio, Inc. - ISEE

Retrieved on: 
Tuesday, May 2, 2023
Class Action Lawsuit, Professional Services, Legal, ISEE, KSF, Sale

and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of IVERIC bio, Inc. (NasdaqGS: ISEE) to Astellas Pharma Inc.

Key Points: 
  • and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of IVERIC bio, Inc. (NasdaqGS: ISEE) to Astellas Pharma Inc.
  • Under the terms of the proposed transaction, shareholders of IVERIC will receive $40.00 in cash for each share of IVERIC that they own.
  • KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

ISEE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Iveric bio, Inc. Is Fair to Shareholders

Retrieved on: 
Monday, May 1, 2023
Legal, Professional Services, ISEE, Fraud, Astellas Pharma, Advertising, Sale, Security (finance), Iver Johnson AMAC-1500

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Iveric bio, Inc. (NASDAQ: ISEE) to Astellas Pharma Inc. for $40.00 per share in cash is fair to Iveric shareholders.

Key Points: 
  • Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Iveric bio, Inc. (NASDAQ: ISEE) to Astellas Pharma Inc. for $40.00 per share in cash is fair to Iveric shareholders.
  • On behalf of Iveric shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.
  • Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Astellas Enters Into Definitive Agreement to Acquire Iveric Bio

Retrieved on: 
Monday, May 1, 2023
Other Professional Services, Biotechnology, Pharmaceutical, Finance, Health, Professional Services, Clinical Trials, Other Health, Therapy, Visual impairment, Bio, AMD, Policy, ISEE, Calendar, NDA, Fezolinetant, Geographic atrophy, Retina, GA, Acquisition, Patent, Patient, Ophthalmology, Biology, R, FDA, Hand, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, ACP, Food, TSE, C5, Medical imaging, Pharmaceutical industry, Marketing, Astellas Pharma, MD

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and IVERIC Bio, Inc. (NASDAQ: ISEE, CEO: Glenn P. Sblendorio, “Iveric Bio”) today announced that on April 29, 2023 (Japan time), the Companies have entered into a definitive agreement under which Astellas through Berry Merger Sub, Inc., a wholly-owned subsidiary of Astellas US Holding, Inc., has agreed to acquire 100% of the outstanding shares of Iveric Bio for US$40.00 per share in cash for a total equity value of approximately US$5.9 billion (the “Acquisition”).

Key Points: 
  • Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and IVERIC Bio, Inc. (NASDAQ: ISEE, CEO: Glenn P. Sblendorio, “Iveric Bio”) today announced that on April 29, 2023 (Japan time), the Companies have entered into a definitive agreement under which Astellas through Berry Merger Sub, Inc., a wholly-owned subsidiary of Astellas US Holding, Inc., has agreed to acquire 100% of the outstanding shares of Iveric Bio for US$40.00 per share in cash for a total equity value of approximately US$5.9 billion (the “Acquisition”).
  • In the Acquisition, Iveric Bio will become an indirectly wholly-owned subsidiary of Astellas.
  • The total equity value of Iveric Bio in the Acquisition assumes that there are approximately 148.2 million outstanding shares of Iveric Bio common stock on a fully diluted basis.
  • “We are pleased to reach an agreement with Iveric Bio, a company with exceptional expertise in the R&D of innovative therapeutics in the ophthalmology field,” said Naoki Okamura, President and CEO, Astellas.

Iveric Bio Announces New Functional Vision Loss Reduction Data from Avacincaptad Pegol GATHER Trials Presented at ARVO Annual Meeting

Retrieved on: 
Sunday, April 23, 2023
Health, Clinical Trials, Research, Science, Pharmaceutical, Optical, Biotechnology, ARVO, Anatomy, ISEE, Geographic atrophy, Month, HIV disease progression rates, Patient, Growth, Association for Research in Vision and Ophthalmology, Paratriathlon, Visual acuity, ACP, Ophthalmology

IVERIC bio, Inc. (Nasdaq: ISEE) today announced new findings from exploratory analyses of data for avacincaptad pegol (ACP), which were presented today at the 2023 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO), in New Orleans.

Key Points: 
  • IVERIC bio, Inc. (Nasdaq: ISEE) today announced new findings from exploratory analyses of data for avacincaptad pegol (ACP), which were presented today at the 2023 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO), in New Orleans.
  • View the full release here: https://www.businesswire.com/news/home/20230423005028/en/
    ACP, avacincaptad pegol; BCVA, best corrected visual acuity; GA, geographic atrophy.
  • Without BCVA (vision) loss group was defined as patients who had a change in BCVA from baseline at Month 12 less than the categorical value.
  • Persistent vision loss was defined as a loss of ≥15 letters in Best Corrected Visual Acuity (BCVA) from baseline measured at any two consecutive visits up to month 12.

Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, April 4, 2023
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Optical, Other Science, Science, ISEE, Employment, Retina

IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on April 3, 2023, the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to nine newly-hired, non-executive employees.

Key Points: 
  • IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on April 3, 2023, the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to nine newly-hired, non-executive employees.
  • The inducement grants consisted of non-statutory stock options to purchase 166,000 shares of the Company’s common stock and 27,000 restricted stock units for shares of the Company’s common stock.
  • The inducement grants are subject to the terms and conditions of award agreements covering the grants and the Company’s 2019 Inducement Stock Incentive Plan.
  • Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs.

Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, March 2, 2023
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, Employment, Retina, ISEE, Pharmaceutical industry

IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on March 1, 2023, the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to nine newly-hired, non-executive employees.

Key Points: 
  • IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on March 1, 2023, the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to nine newly-hired, non-executive employees.
  • The inducement grants consisted of non-statutory stock options to purchase 107,000 shares of the Company’s common stock and 11,110 restricted stock units for shares of the Company’s common stock.
  • The inducement grants are subject to the terms and conditions of award agreements covering the grants and the Company’s 2019 Inducement Stock Incentive Plan.
  • Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs.